The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

The approval is for Eylea to treat macular edema following retinal vein occlusion with up to every eight-week dosing after an initial dosing period. The FDA also approved a monthly dosing option for ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

A 2025 review shows India’s preterm birth rate at 13%. With over 23% of global preterm births, nearly 150,000 Indian infants ...

Family medical history and preexisting health conditions are among the many risk factors for retinal detachment. I’m at high risk thanks to several factors, and it makes me nervous. Anyone can develop ...

Regeneron Pharmaceuticals has announced the U.S. FDA's acceptance for Priority Review of the supplemental Biologics License Application for EYLEA HD (aflibercept) Injection 8 mg, which, if approved, ...

CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ -- Pykus Therapeutics, Inc. ("Pykus" or the "Company") announced today that it has completed enrollment of its pilot study (PYK-2101-RD001) in Australia.

Risk of proliferative vitreoretinopathy within 6 months of primary retinal detachment is lower in patients receiving systemic methotrexate or azathioprine therapy. Systemic methotrexate and ...